Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of CytomX Therapeutics Inc (NASDAQ: CTMX) was $1.13 for the day, up 6.60% from the previous closing price of $1.06. In other words, the price has increased by $6.60 from its previous closing price. On the day, 0.73 million shares were traded. CTMX stock price reached its highest trading level at $1.13 during the session, while it also had its lowest trading level at $1.08.
Ratios:
Our analysis of CTMX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 20 ’24 when Landau Jeffrey B sold 4,181 shares for $1.23 per share. The transaction valued at 5,139 led to the insider holds 119,056 shares of the business.
BELVIN MARCIA sold 4,181 shares of CTMX for $5,139 on Aug 20 ’24. The SVP, Chief Scientific Officer now owns 175,648 shares after completing the transaction at $1.23 per share. On Aug 20 ’24, another insider, ROWLAND LLOYD A, who serves as the General Counsel of the company, sold 4,181 shares for $1.23 each. As a result, the insider received 5,139 and left with 130,797 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 88432552 and an Enterprise Value of -18558466. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74. Its current Enterprise Value per Revenue stands at -0.147 whereas that against EBITDA is -2.17.
Stock Price History:
Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is 7.13%, while the 200-Day Moving Average is calculated to be -22.86%.
Shares Statistics:
CTMX traded an average of 1.16M shares per day over the past three months and 1055300 shares per day over the past ten days. A total of 78.23M shares are outstanding, with a floating share count of 76.94M. Insiders hold about 1.69% of the company’s shares, while institutions hold 65.49% stake in the company. Shares short for CTMX as of 1734048000 were 5541656 with a Short Ratio of 4.78, compared to 1731628800 on 4438441. Therefore, it implies a Short% of Shares Outstanding of 5541656 and a Short% of Float of 7.13.
